Ranibizumab

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Conditions

Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

Trial Timeline

Dec 15, 2016 → Dec 28, 2018

NCT ID

NCT02953938

About Ranibizumab

Ranibizumab is a approved stage product being developed by Novartis for Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO). The current trial status is completed. This product is registered under clinical trial identifier NCT02953938. Target conditions include Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO).

What happened to similar drugs?

20 of 20 similar drugs in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) were approved

Approved (20) Terminated (3) Active (0)

✅FYB203 2 mg (0.05 mL of 40 mg/mL)Formycon AGApproved

✅FYB201 0.5 mg (0.05 mL of 10 mg/mL)Formycon AGApproved

✅Aflibercept Injection [Eylea]Santen PharmaceuticalApproved

✅Ozurdex + AfliberceptAbbVieApproved

✅RanibizumabNovartisApproved

✅ranibizumabNovartisApproved

✅intravitreal injection of Brolucizumab 6 mg in study eyeNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04464694	Approved	UNKNOWN	Sep 1, 2020	Jun 1, 2022	Proliferative Diabetic Retinopathy
NCT02953938	Approved	Completed	Dec 15, 2016	Dec 28, 2018	Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
NCT02976194	Approved	UNKNOWN	Nov 22, 2016	Jan 1, 2020	Exudative Age-related Macular Degeneration
NCT02843490	Approved	Completed	Aug 5, 2016	Nov 9, 2017	Neovascular Age-related Macular Degeneration
NCT02640664	Phase 3	Completed	Jun 16, 2016	Apr 21, 2022	Retinopathy of Prematurity (ROP)
NCT02707575	Pre-clinical	Completed	Apr 26, 2016	Apr 23, 2018	Age-related Macular Degeneration
NCT02634970	Approved	Withdrawn	Mar 1, 2016	Dec 1, 2017	Wet Age-related Macular Degeneration (Wet AMD)
NCT02375971	Phase 3	Completed	Dec 30, 2015	Dec 14, 2017	Retinopathy of Prematurity
NCT02329132	Pre-clinical	Completed	Nov 1, 2015	Feb 28, 2018	Diabetic Macular Edema
NCT02161575	Approved	Completed	Aug 28, 2014	Sep 14, 2017	Neovascular Age-related Macular Degeneration
NCT02034006	Phase 3	Completed	Jun 10, 2014	Jul 15, 2016	Choroidal Neovascularization Secondary to Pathologic Myopia
NCT02059772	Approved	UNKNOWN	Apr 30, 2014	Dec 31, 2017	Diabetic Macular Edema
NCT01986907	Approved	Completed	Mar 4, 2014	Jun 15, 2016	Wet Age Related Macular Degeneration
NCT02055911	Approved	Withdrawn	Mar 1, 2014	Jul 1, 2015	Diabetic Macular Edema
NCT02478515	Approved	Completed	Jan 1, 2014	Mar 1, 2019	Branch Retinal Vein Occlusion
NCT01972789	Approved	Completed	Oct 31, 2013	Feb 28, 2017	Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
NCT01846299	Phase 3	Completed	Oct 1, 2013	Sep 1, 2015	Macular Edema (ME)
NCT01908816	Phase 3	Completed	Sep 26, 2013	Jan 8, 2016	Choroidal Neovascularization
NCT01840410	Phase 3	Completed	Sep 1, 2013	Nov 1, 2015	Choroidal Neovascularization (CNV)
NCT01780935	Phase 3	Completed	Jun 3, 2013	Jul 9, 2015	Neovascular Age-related Macular Degeneration

Competing Products

20 competing products in Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)

See all competitors

Product	Company	Stage	Hype Score
IVT aflibercept + Sham SC + SC CLS-TA	Clearside Biomedical	Phase 2	25
CLS-AX + Anti-VEGF	Clearside Biomedical	Phase 1/2	22
4 mg CLS-TA + Sham + IVT aflibercept	Clearside Biomedical	Phase 2	25
suprachoroidal CLS-TA + suprachoroidal sham + Lucentis or Avastin	Clearside Biomedical	Phase 3	22
CLS-AX + Aflibercept	Clearside Biomedical	Phase 2	25
Eylea + ALT-L9	Alteogen	Phase 1	29
KVD001 Injection	KalVista Pharmaceuticals	Phase 2	29
KVD001 Injection	KalVista Pharmaceuticals	Phase 1	23
FYB203 2 mg (0.05 mL of 40 mg/mL)	Formycon AG	Approved	33
FYB201 0.5 mg (0.05 mL of 10 mg/mL)	Formycon AG	Approved	33
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)	Unity Biotechnology	Phase 2	25
UBX1325	Unity Biotechnology	Phase 2	25
Aflibercept + foselutoclax	Unity Biotechnology	Phase 2	25
UBX1325	Unity Biotechnology	Phase 1	19
CT-P42 + Eylea	Celltrion	Phase 3	40
Faricimab + Aflibercept	Chugai Pharmaceutical	Phase 3	40
Faricimab + Aflibercept	Chugai Pharmaceutical	Phase 3	40
DS-7080a + Ranibizumab	Daiichi Sankyo	Phase 1	29
Fovista® + bevacizumab + ranibizumab + aflibercept	Astellas Pharma	Phase 2	27
MA09-hRPE	Astellas Pharma	Pre-clinical	26